Neurochem (international) Limited

Bhi Limited Partnership

Bellus Health Inc.

Queen's University at Kingston

Bellus Health (international) Limited

Kiacta Sarl

David Migneault

Xianqi Kong

Xinfu Wu

Isabelle Valade

Daniel Delorme

Abderrahim Bouzide

Benoit Bachand

Sophie Levesque

Mohamed Atfani

Francine Gervais

Stephane Ciblat

Donald F Weaver

Walter A Szarek

Ajay Gupta

Bita Samim

Stéphane Ciblat

Robert Chalifour

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Method and compositions for treating amyloid-related diseases

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

Methods and compounds for inhibiting amyloid deposits

Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

Amyloid targeting imaging agents and uses thereof

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 

Amidine derivatives for treating amyloidosis

The present invention is directed to methods of preparation of sulfonate derivatized compounds, e.g., 3-amino-1-propanesulfonic acid and 1,3-propanedisulfonic acid disodium salt with increased purity, with reduced potential for toxic by-products, and that are pharmaceutically useful, e.g., for the treatment of amyloidosis.

Pharmaceutical drug candidates and methods for preparation thereof

Growing community of inventors

Laval, Canada

David Migneault